← All trials
NCT05034536
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2022
- Primary completion
- Jun 30, 2023
- Completion date
- Jun 30, 2025
- First posted
- Sep 5, 2021
- Last posted
- Sep 5, 2021
- Enrollment
- 36
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Harvard UniversityLead sponsor
- Harvard UniversityOverall official - principal investigator
- Harvard UniversityReponsible party - principal investigator
- Massachusetts Institute of TechnologyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.